BENGALURU (Reuters) – U.S. drugmaker Eli Lilly and Co said on Tuesday its antibody drug combination has received an emergency use approval in India for the treatment of mild to moderate COVID-19 cases.
(Reporting by Anuron Kumar Mitra in Bengaluru; editing by Uttaresh.V)
